Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lundbeck CEO: Alder Buy Will Boost Pipeline

Sep 16 2019

• By Sten Stovall

Road_Sign — $1.95bn cash acquisition of Alder sees Lundbeck gain eptinezumab to treat migraines. • Source: Shutterstock

Related Content

Lundbeck Boosts US R&D Capability With $400m Abide Theraputics Bid

May 06 2019

Related Companies

Alder Biopharmaceuticals, Inc.

H. Lundbeck A/S

Abide Therapeutics Inc.

Additional Topics

Deals Commercial Companies Neurology BioPharmaceutical

More from Deals

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.